- Home
- ROIV vs BXSL Comparison
ROIV vs BXSL Comparison
Compare ROIV & BXSL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ROIV
- BXSL
- Stock Information
- Founded
- ROIV 2014
- BXSL 2018
- Country
- ROIV United Kingdom
- BXSL United States
- Employees
- ROIV N/A
- BXSL N/A
- Industry
- ROIV Biotechnology: Pharmaceutical Preparations
- BXSL Trusts Except Educational Religious and Charitable
- Sector
- ROIV Health Care
- BXSL Finance
- Exchange
- ROIV Nasdaq
- BXSL Nasdaq
- Market Cap
- ROIV 8.6B
- BXSL 7.3B
- IPO Year
- ROIV N/A
- BXSL N/A
- Fundamental
- Price
- ROIV $14.14
- BXSL $27.54
- Analyst Decision
- ROIV Strong Buy
- BXSL Buy
- Analyst Count
- ROIV 4
- BXSL 7
- Target Price
- ROIV $15.50
- BXSL $31.32
- AVG Volume (30 Days)
- ROIV 6.7M
- BXSL 1.3M
- Earning Date
- ROIV 11-11-2025
- BXSL 11-11-2025
- Dividend Yield
- ROIV N/A
- BXSL 11.11%
- EPS Growth
- ROIV N/A
- BXSL N/A
- EPS
- ROIV N/A
- BXSL 2.83
- Revenue
- ROIV $23,233,000.00
- BXSL $1,398,444,000.00
- Revenue This Year
- ROIV N/A
- BXSL $4.83
- Revenue Next Year
- ROIV $281.14
- BXSL $3.95
- P/E Ratio
- ROIV N/A
- BXSL $9.81
- Revenue Growth
- ROIV N/A
- BXSL 14.70
- 52 Week Low
- ROIV $8.73
- BXSL $25.89
- 52 Week High
- ROIV $14.48
- BXSL $34.64
- Technical
- Relative Strength Index (RSI)
- ROIV 74.50
- BXSL 49.98
- Support Level
- ROIV $13.81
- BXSL N/A
- Resistance Level
- ROIV $14.48
- BXSL $29.57
- Average True Range (ATR)
- ROIV 0.42
- BXSL 0.34
- MACD
- ROIV 0.16
- BXSL -1.15
- Stochastic Oscillator
- ROIV 85.52
- BXSL 91.39
About ROIV Roivant Sciences Ltd.
Roivant Sciences Ltd is a commercial-stage biopharmaceutical company dedicated to improving the delivery of healthcare to patients. It also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business. Its drug candidate VTAMA (tapinarof) is a treatment of plaque psoriasis in adult patients and is in its commercial stage. The other drug candidates in their different stages of development are; Batoclimab, IMVT-1402, Brepocitinib, Namilumab, and others.
About BXSL Blackstone Secured Lending Fund of Beneficial Interest
Blackstone Secured Lending Fund is a non-diversified, closed-end management investment company. The investment objectives of the company are to generate current income and, to a lesser extent, long-term capital appreciation. The company seeks to achieve its investment objectives by investing in originated loans and other securities, including syndicated loans of private U.S. companies, typically in the form of first lien senior secured and unitranche loans, unsecured and subordinated loans, and other securities.